Prelude Therapeutics (PRLD) Depreciation & Amortization (CF) (2019 - 2026)

Prelude Therapeutics has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $391000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $391000.0, down 10.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (down 6.4% YoY), and the FY2025 annual result was $1.7 million, down 3.44% from the prior year.
• Depreciation & Amortization (CF) came in at $391000.0 for Q1 2026 at Prelude Therapeutics, down from $418000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $489000.0 in Q4 2024 to a low of $278000.0 in Q1 2023.
• The 5-year median for Depreciation & Amortization (CF) is $391000.0 (2026), against an average of $374529.4.
• Across the five-year window, Depreciation & Amortization (CF) soared 91.88% in 2022 and retreated 17.21% in 2023, its largest moves.
• Prelude Therapeutics' Depreciation & Amortization (CF) stood at $362000.0 in 2022, then fell by 8.56% to $331000.0 in 2023, then soared by 47.73% to $489000.0 in 2024, then slipped by 14.52% to $418000.0 in 2025, then declined by 6.46% to $391000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $391000.0 (Q1 2026), $418000.0 (Q4 2025), and $425000.0 (Q3 2025), per Business Quant data.